Sol-Gel Technologies Ltd. (SLGL)

Market Cap	16.16M
Revenue (ttm)	11.71M
Net Income (ttm)	-9.57M
Shares Out	27.86M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,857
Open	0.570
Previous Close	0.608
Day's Range	0.570 - 0.600
52-Week Range	0.334 - 1.650
Beta	1.31
Analysts	Strong Buy
Price Target	5.00 (+762.07%)
Earnings Date	Mar 12, 2025

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hype...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL
• Website: https://www.sol-gel.com

Financial Performance

In 2023, Sol-Gel Technologies's revenue was $1.55 million, a decrease of -59.98% compared to the previous year's $3.88 million. Losses were -$27.24 million, 82.5% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 762.07% from the latest price.

Price Target

$5.0

(762.07% upside)

Analyst Consensus: Strong Buy